Lam, J U H
Elfström, K M
Ejegod, D M
Pedersen, H
Rygaard, C
Rebolj, M
Lynge, E
Juul, K E
Kjær, S K
Dillner, J
Bonde, J
Article History
Received: 10 April 2017
Revised: 15 September 2017
Accepted: 26 September 2017
First Online: 14 November 2017
Competing interests
: JUHL attended meetings with various HPV device manufacturers. MR attended meetings with various HPV device manufacturers. She and her former employer received fees for lectures on her behalf from Qiagen. DME attended meetings with various HPV device manufacturers. She received honoraria from BD and Qiagen for lectures. HP attended meetings with various HPV device manufacturers. CR participated in meetings with Roche with fee paid to the University of Copenhagen. EL participated in meetings with Roche and Astra-Zeneca with fees paid to the University of Copenhagen, and was unpaid advisor to GenProbe and NorChip. Roche has provided test kits to Trial23. SKK has received lecture fees, scientific advisory board fees from Merck, Sanofi Pasteur MSD, BD, and unrestricted research grants through the affiliating institute from Merck. JD has received grants to his institution for studies on HPV vaccination from Merck/SPMSD. JB attended meetings with various HPV device manufacturers. He used to serve as a paid advisor to Roche and Genomica, and has received honoraria from Hologic/Gen-Probe, Roche, Qiagen, Genomica, and BD Diagnostics for lectures. He is principal investigator on studies funded by BD diagnostics. Hvidovre Hospital holds a recompense agreement with Genomica on a KRAS/BRAF diagnostic system. KME and KEJ declare no conflict of interest.